论文部分内容阅读
目的探讨利妥昔单抗联合CHOP方案治疗弥漫大B细胞淋巴瘤(DLBCL)对患者远期生存率的影响。方法将84例初治DLBCL患者随机分为对照组和观察组,各42例。对照组患者采用传统CHOP方案化疗,观察组患者采用利妥昔单抗联合CHOP(R-CHOP)方案化疗,观察疗效指标,比较两组患者不良反应发生率间差异。结果观察组患者完全缓解(CR)率较对照组显著提高(P<0.05),两组患者部分缓解(PR)率未见明显差异(P>0.05)。观察组患者总有效率较对照组显著提高(P<0.05)。两组患者1年无进展生存(PFS)率、总体生存(OS)率等间均无明显差异(P>0.05),而观察组患者3年PFS率及OS率均较对照组明显增高(P<0.05)。治疗过程中两组患者不良事件发生率未见明显差异(P>0.05)。结论 R-CHOP方案治疗DLBCL过程安全、有效,较传统方案联合方案能显著改善患者长期生存率。
Objective To investigate the effect of rituximab combined with CHOP regimen on the long-term survival of patients with diffuse large B-cell lymphoma (DLBCL). Methods 84 cases of newly diagnosed DLBCL patients were randomly divided into control group and observation group, 42 cases in each group. Patients in the control group were treated with conventional CHOP chemotherapy. Patients in the observation group were treated with rituximab combined with CHOP (R-CHOP) regimen. Efficacy indicators were compared and the difference in adverse reactions between the two groups was compared. Results The complete remission (CR) rate of the observation group was significantly higher than that of the control group (P <0.05). There was no significant difference in the partial response (PR) between the two groups (P> 0.05). The total effective rate in observation group was significantly higher than that in control group (P <0.05). There was no significant difference in one-year progression-free survival (PFS) rate and overall survival (OS) between the two groups (P> 0.05), while PFS and OS rates in the observation group were significantly higher than those in the control group (P <0.05). There was no significant difference in the incidence of adverse events between the two groups during treatment (P> 0.05). Conclusion The R-CHOP regimen is safe and effective in treating DLBCL. Compared with the traditional regimen, the long-term survival rate can be significantly improved.